Bristol-Myers Squibb (BMY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.35
- Estimate
- $1.17
- Surprise
- +14.9%
- Revenue (period 2026-09-30)
- $13.07B
- Score today
- 6.6/10
Revenue source: xbrl.
How the report landed
Bristol-Myers Squibb (BMY) beat the $1.17 estimate with adjusted EPS of $1.35 — a large 14.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BMY Buy (Wait) at 6.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +14.9% surprise compares with a +14.6% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Geographic: United States (69.0%)
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 2.0): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $61.39
- Entry target
- $57.09
- Stop
- $54.47
The stock trades at 13.5× trailing but 9.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
BMY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $125.40B
- P/E (fwd)
- 9.3
- P/E (ttm)
- 13.5
- 52-week range
- $43.20–$68.64
- Off 52-week high
- 10.6%
- RSI (14)
- 57
- Volume vs avg
- 1.19×
- Score today
- 6.6/10